Sugi Predict

Sugi Predict / Targets / CDR2

CDR2

Cerebellar degeneration-related protein 2 · Q01850 · CDR2 on Sugi Atlas →

0 patent compounds predicted against CDR2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CDR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Open Trail of γIFN for Friedreich Ataxia PHASE2COMPLETED
Study of CAD-1883 for Spinocerebellar Ataxia PHASE2WITHDRAWN
High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration PHASE2COMPLETED
Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases nanACTIVE_NOT_RECRUITING
Core Stability Exercises and Hereditary Ataxia nanCOMPLETED
Biomarker Research in Inherited Movement Disorders nanRECRUITING
Home Exercise for Individuals with Neurodegenerative Disease nanRECRUITING
Natural History of Spinocerebellar Ataxia Type 7 (SCA7) nanRECRUITING
Biomarkers in Autosomal Dominant Cerebellar Ataxia nanCOMPLETED
Validation of the RADIAL Algorithm for Diagnosis of Autosomal Recessive Cerebellar Ataxia nanRECRUITING
Identification of Biomarkers in Spinocerebellar Ataxia 3 nanCOMPLETED
Efficacy of tDCS in Degenerative Ataxia nanACTIVE_NOT_RECRUITING
Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T nanCOMPLETED
Sporadic Degenerative Ataxia With Adult Onset: Natural History Study nanRECRUITING
Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations nanCOMPLETED
Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia nanCOMPLETED
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia nanCOMPLETED
A Controlled Comparison of Two DBS Targets for Upper Extremity Action Tremor nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
The Benefits of Long-read High-throughput Genomic Sequencing for the Causal Diagnosis of Cerebellar Ataxias nanRECRUITING
Brain Network Activation in Patients With Movement Disorders nanUNKNOWN
Biomarker of Children With Familial Autoimmune History nanCOMPLETED
Gluten-Free Diet in Patients With Gluten Sensitivity and Cerebellar Ataxia nanCOMPLETED
Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias nanCOMPLETED
Hereditary Ataxia Research on Multi-Omics and Neuroclinical Insights in the Yangtze Delta nanRECRUITING
Structural Validity and Inter-rater Reliabitiliy of the Ataxia Trunk, Lower And Upper Extremity Scale (ATLAS) nanNOT_YET_RECRUITING
Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD） nanRECRUITING
Coordination Training With Complete Body Video Games in Children and Adults With Degenerative Ataxias nanCOMPLETED
Advancing Neurogenetic Diagnoses Through Long-Read Sequencing nanNOT_YET_RECRUITING
Docosahexaenoic Acid (DHA) Replacement for Treatment in Spinocerebellar Ataxia 38 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CDR2 binder may also engage these)

ProteinNameSimilarity
P97817 — 1.000 P97817 →
Q5ZJA3 — 0.998 Q5ZJA3 →
Q9QYP6 — 0.991 Q9QYP6 →
Q4R3X1 — 0.991 Q4R3X1 →
Q5U465 — 0.990 Q5U465 →
P0C219 — 0.989 P0C219 →
Q4KMA0 — 0.989 Q4KMA0 →
Q3SYW5 — 0.988 Q3SYW5 →
Q96G01 — 0.987 Q96G01 →
Q5R4U3 — 0.986 Q5R4U3 →
Q17QG3 — 0.986 Q17QG3 →
Q9H2G9 — 0.986 Q9H2G9 →
Q5RCR6 — 0.986 Q5RCR6 →
Q8N4C6 — 0.985 Q8N4C6 →
Q8IYY4 — 0.985 Q8IYY4 →
D3YV10 — 0.985 D3YV10 →
D3ZUQ0 — 0.984 D3ZUQ0 →
Q5RD40 — 0.984 Q5RD40 →
Q921M4 — 0.984 Q921M4 →
Q2KJE0 — 0.984 Q2KJE0 →
A2A6T1 — 0.984 A2A6T1 →
Q8IYE1 — 0.984 Q8IYE1 →
Q969X0 — 0.984 Q969X0 →
Q86Z20 — 0.984 Q86Z20 →
Q6DH86 — 0.984 Q6DH86 →
Q86X02 — 0.984 Q86X02 →
Q6ZUS6 — 0.983 Q6ZUS6 →
Q9JHZ4 — 0.983 Q9JHZ4 →
Q0IHE5 — 0.983 Q0IHE5 →
Q99LE1 — 0.983 Q99LE1 →